United Therapeutics Revenue and Competitors

Location

$70M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • United Therapeutics's estimated annual revenue is currently $1.7B per year.(i)
  • United Therapeutics's estimated revenue per employee is $1,663,327
  • United Therapeutics's total funding is $70M.
  • United Therapeutics's current valuation is $9.6B. (January 2022)

Employee Data

  • United Therapeutics has 998 Employees.(i)

United Therapeutics's People

NameTitleEmail/Phone
1
Associate VP, Operational TechnologyReveal Email/Phone
2
Associate VP, Medical Device OperationsReveal Email/Phone
3
Sr. VP Sales & MarketingReveal Email/Phone
4
Associate VP, Global Regulatory AffairsReveal Email/Phone
5
Sr. VP & Chief Medical Officer, Lung Biotechnology, PBCReveal Email/Phone
6
Associate VP Managed Markets and ReimbursementReveal Email/Phone
7
SVP and Chief Medical Officer - North AmericaReveal Email/Phone
8
VP, Associate General Counsel, Market AccessReveal Email/Phone
9
Executive Director, Clinical Safety OfficerReveal Email/Phone
10
VP Business and Legal AffairsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$7M35-3%N/AN/A
#2
$7.2M36-5%N/AN/A
#3
$10.5M52-9%N/AN/A
#4
$344.1M17129%N/AN/A
#5
$27.5M1376%N/AN/A
#6
$107.3M5349%N/AN/A
#7
$12.9M6428%N/AN/A
#8
$31.6M1571%N/AN/A
#9
$31.4M1567%N/AN/A
#10
$11.5M5730%N/AN/A
Add Company

What Is United Therapeutics?

United Therapeutics is a biotechnology company focused on the development and commercialization of unique products for patients with chronic and life-threatening cardiovascular, cancer and infectious diseases. In these segments, United Therapeutics is actively developing four technology platforms: Prostacyclin Analogs, Immunotherapeutic Monoclonal Antibodies, Glycobiology, and Telemedicine.

keywords:N/A

$70M

Total Funding

998

Number of Employees

$1.7B

Revenue (est)

N/A

Employee Growth %

$9.6B

Valuation

N/A

Accelerator

United Therapeutics News

2022-04-20 - United Therapeutics Hosts Community Meeting on Initial ...

United Therapeutics Hosts Community Meeting on Initial Concept for New Office Building. Mike Diegel | April 21, 2022 | Categories Silver Spring.

2022-04-13 - Liquidia opens $50M offering amid patent dispute with United ...

In 2020, United Therapeutics (Nasdaq: UTHR) – which has a headquarters in the Triangle – sued Liquidia for alleged patent infringement...

2022-04-06 - United Therapeutics Announces the Publication of Tyvaso DPI ...

United Therapeutics Announces the Publication of Tyvaso DPI™ BREEZE Clinical and Long-term Data in the Journal Pulmonary Circulation.

2021-08-04 - United Therapeutics Corporation : Reports Second Quarter 2021 Financial Results

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 4, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended June 30, 2021. Total revenue in the second quarter of 2021 grew 23% year over year to $446.5 million, compa ...

2021-08-04 - United Therapeutics : Tyvaso® (treprostinil) Inhalation Solution net revenue growth of 29% year over year; total net revenue growth of 23% year over year Tyvaso DPI™ NDA under review with FDA action expected in October 2021 (Form 8-K)

Tyvaso® (treprostinil) Inhalation Solution net revenue growth of 29% year over year; total net revenue growth of 23% year over year Tyvaso DPI™ NDA under review with FDA action expected in October 2021 SILVER SPRING, MD. and RESEARCH TRIANGLE PARK, N.C., August 4, 2021: United Therapeutics Cor ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$467.1M10119%N/A
#2
$75M15329%N/A
#3
$75M213351%N/A
#4
$770.3M26206%N/A
#5
$1389.9M36776%N/A